CBLL
$19.48+0.32 (+1.67%)
CeriBell, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company ...
Recent News
CeriBell Conference: CFO Highlights 36% Revenue Growth, Expands EEG Platform to Pediatrics and Delirium
CeriBell (NASDAQ:CBLL) is seeking to accelerate adoption of its point-of-care EEG platform in U.S. hospitals while expanding into new patient populations and indications, Chief Financial Officer Scott Blumberg said at the 47th Annual Raymond James Institutional Investors Conference. Blumberg told i
CeriBell Highlights 2026 Growth Plan at TD Cowen: 25%-29% Guide, VA Ramp, Delirium Pilot
CeriBell (NASDAQ:CBLL) executives outlined the company’s 2026 priorities and growth drivers during a fireside chat at the 46th annual TD Cowen Healthcare Conference, emphasizing continued expansion in hospital adoption, upcoming pediatric and neonatal offerings, early plans for a delirium commercial
Cautious Guidance Offsets Solid Q4 for CeriBell, Inc. (CBLL), Says Canaccord
CeriBell, Inc. (NASDAQ:CBLL) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts. CeriBell, Inc. (NASDAQ:CBLL) secures the twelfth place on our list of most promising stocks. TheFly reported on February 25 that Canaccord reduced its price target for CBLL from $30 to $28 and maintained a Buy rating on the stock. […]
CeriBell Inc (CBLL) Q4 2025 Earnings Call Highlights: Revenue Surge and Market Expansion Amid ...
CeriBell Inc (CBLL) reports significant revenue growth and market expansion, but faces hurdles with net losses and operational expenses.
CeriBell Q4 Earnings Call Highlights
CeriBell (NASDAQ:CBLL) reported fourth-quarter and full-year 2025 results that management said reflected continued penetration of its core seizure market alongside a broadened product and regulatory foundation intended to expand the company’s addressable opportunity. The company also provided 2026 r